サマリー

細胞・遺伝子治療製造市場 - レポートの範囲
TMR社の調査レポート「世界の細胞・遺伝子治療製造市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界の細胞・遺伝子治療製造市場の収益を提供しています。また、2023年から2031年までの世界の細胞・遺伝子治療製造市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照し、細胞・遺伝子治療製造市場を理解しました。

二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれる。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の細胞・遺伝子治療製造市場の様々な属性を調査した。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、世界の細胞・遺伝子治療製造市場における競争ダイナミクスの変化にも光を当てています。これらは、既存の市場関係者だけでなく、世界の細胞・遺伝子治療製造市場への参入に関心のある企業にとっても貴重なツールとなります。

本レポートでは、世界の細胞・遺伝子治療製造市場の競争環境について掘り下げています。世界の細胞・遺伝子治療製造市場で事業を展開する主要企業が特定され、その各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の細胞・遺伝子治療製造市場におけるプレイヤーの属性である。

細胞および遺伝子治療製造の世界市場レポートで回答された主な質問
- 予測期間中の全地域における細胞・遺伝子治療製造が生み出す売上高/収益は？
- 世界の細胞・遺伝子治療製造市場におけるビジネスチャンスは？
- 市場における主な促進要因、阻害要因、機会、脅威は何か？
- 予測期間中に最も速いCAGRで拡大する地域市場はどこか？
- 2031年に世界で最も高い収益を上げると予測されるセグメントは？
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは？
- 世界市場で事業を展開する各企業の市場ポジションは？

細胞・遺伝子治療製造市場 - 調査目的と調査アプローチ
世界の細胞・遺伝子治療製造市場に関する包括的なレポートは、まず概要から始まり、次に調査範囲と目的について説明しています。本レポートでは、本調査の目的、市場で事業展開する主要ベンダーと販売業者、製品承認に関する規制シナリオについて詳細に解説しています。

本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴える。また、過去と予測期間末の主要セグメントの市場シェアを比較することもできる。

本レポートでは、世界の細胞・遺伝子治療製造市場を製品、エンドユーザー、地域の観点から分析している。各基準における主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界の細胞・遺伝子治療製造市場への投資について、情報に基づいたビジネス上の意思決定を行うことが可能になります。

ページTOPに戻る

目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Cell and Gene Therapy Manufacturing Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Technological Advancements
    5.2. Reimbursement Scenario by Region/Globally
    5.3. Regulatory Scenario by Region/globally
    5.4. Disease Prevalence & Incidence Rate Globally With Key Countries
    5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Therapy Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Therapy Type, 2017-2031
        6.3.1. Cell Therapy
            6.3.1.1. Allogeneic
                6.3.1.1.1. Mesenchymal Stem Cells
                6.3.1.1.2. T-cells
                6.3.1.1.3. Induced Pluripotent Stem Cells
                6.3.1.1.4. Natural Killer Cells
                6.3.1.1.5. Hematopoietic Stem Cells
                6.3.1.1.6. Others
            6.3.1.2. Autologous
                6.3.1.2.1. T-cells
                6.3.1.2.2. Hematopoietic Stem Cells
                6.3.1.2.3. Mesenchymal Stem Cells
                6.3.1.2.4. Natural Killer Cells
                6.3.1.2.5. Others
        6.3.2. Gene Therapy
            6.3.2.1. Viral Vector
                6.3.2.1.1. Lentiviral Vector
                6.3.2.1.2. Adeno-associated Virus Vectors
                6.3.2.1.3. Other Viral Vectors
            6.3.2.2. Non-viral Vector
                6.3.2.2.1. Electroporation
                6.3.2.2.2. Other Non-viral Vectors
    6.4. Market Attractiveness Analysis, by Therapy Type
7. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Product Type
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Product Type, 2017-2031
        7.3.1. Consumables
        7.3.2. Equipment
            7.3.2.1. Cell Processing Equipment
            7.3.2.2. Single-use Equipment
            7.3.2.3. Other Equipment
        7.3.3. Software & Systems
    7.4. Market Attractiveness Analysis, by Product Type
8. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Technology
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Technology, 2017-2031
        8.3.1. Cell Culture & Expansion
        8.3.2. Viral Vector Production
        8.3.3. Cell Sorting & Purification
        8.3.4. Gene Editing
        8.3.5. Others
    8.4. Market Attractiveness Analysis, by Technology
9. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Indication
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Indication, 2017-2031
        9.3.1. Oncology Disease
        9.3.2. Cardiovascular Disease
        9.3.3. Orthopedic Disease
        9.3.4. Infectious Disease
        9.3.5. Others
    9.4. Market Attractiveness Analysis, by Indication
10. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by End-user
    10.1. Introduction & Definition
    10.2. Key Findings/Developments
    10.3. Market Value Forecast, by End-user, 2017-2031
        10.3.1. Pharmaceutical & Biotechnology Companies
        10.3.2. Contract Manufacturing Organizations (CMOs)
    10.4. Market Attractiveness Analysis, by End-user
11. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Region
    11.1. Key Findings
    11.2. Market Value Forecast, by Region, 2017-2031
        11.2.1. North America
        11.2.2. Europe
        11.2.3. Asia Pacific
        11.2.4. Latin America
        11.2.5. Middle East & Africa
    11.3. Market Attractiveness Analysis, by Region
12. North America Cell and Gene Therapy Manufacturing Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Therapy Type, 2017-2031
        12.2.1. Cell Therapy
            12.2.1.1. Allogeneic
                12.2.1.1.1. Mesenchymal Stem Cells
                12.2.1.1.2. T-cells
                12.2.1.1.3. Induced Pluripotent Stem Cells
                12.2.1.1.4. Natural Killer Cells
                12.2.1.1.5. Hematopoietic Stem Cells
                12.2.1.1.6. Others
            12.2.1.2. Autologous
                12.2.1.2.1. T-cells
                12.2.1.2.2. Hematopoietic Stem Cells
                12.2.1.2.3. Mesenchymal Stem Cells
                12.2.1.2.4. Natural Killer Cells
                12.2.1.2.5. Others
        12.2.2. Gene Therapy
            12.2.2.1. Viral Vector
                12.2.2.1.1. Lentiviral Vector
                12.2.2.1.2. Adeno-associated Virus Vectors
                12.2.2.1.3. Other Viral Vectors
            12.2.2.2. Non-viral Vector
                12.2.2.2.1. Electroporation
                12.2.2.2.2. Other Non-viral Vectors
    12.3. Market Value Forecast, by Product Type, 2017-2031
        12.3.1. Consumables
        12.3.2. Equipment
            12.3.2.1. Cell Processing Equipment
            12.3.2.2. Single-use Equipment
            12.3.2.3. Other Equipment
        12.3.3. Software & Systems
    12.4. Market Value Forecast, by Technology, 2017-2031
        12.4.1. Cell Culture & Expansion
        12.4.2. Viral Vector Production
        12.4.3. Cell Sorting & Purification
        12.4.4. Gene Editing
        12.4.5. Others
    12.5. Market Value Forecast, by Indication, 2017-2031
        12.5.1. Oncology Disease
        12.5.2. Cardiovascular Disease
        12.5.3. Orthopedic Disease
        12.5.4. Infectious Disease
        12.5.5. Others
    12.6. Market Value Forecast, by End-user, 2017-2031
        12.6.1. Pharmaceutical & Biotechnology Companies
        12.6.2. Contract Manufacturing Organizations (CMOs)
    12.7. Market Value Forecast, by Country, 2017-2031
        12.7.1. U.S.
        12.7.2. Canada
    12.8. Market Attractiveness Analysis
        12.8.1. By Therapy Type
        12.8.2. By Product Type
        12.8.3. By Technology
        12.8.4. By Indication
        12.8.5. By End-user
        12.8.6. By Country
13. Europe Cell and Gene Therapy Manufacturing Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Therapy Type, 2017-2031
        13.2.1. Cell Therapy
            13.2.1.1. Allogeneic
                13.2.1.1.1. Mesenchymal Stem Cells
                13.2.1.1.2. T-cells
                13.2.1.1.3. Induced Pluripotent Stem Cells
                13.2.1.1.4. Natural Killer Cells
                13.2.1.1.5. Hematopoietic Stem Cells
                13.2.1.1.6. Others
            13.2.1.2. Autologous
                13.2.1.2.1. T-cells
                13.2.1.2.2. Hematopoietic Stem Cells
                13.2.1.2.3. Mesenchymal Stem Cells
                13.2.1.2.4. Natural Killer Cells
                13.2.1.2.5. Others
        13.2.2. Gene Therapy
            13.2.2.1. Viral Vector
                13.2.2.1.1. Lentiviral Vector
                13.2.2.1.2. Adeno-associated Virus Vectors
                13.2.2.1.3. Other Viral Vectors
            13.2.2.2. Non-viral Vector
                13.2.2.2.1. Electroporation
                13.2.2.2.2. Other Non-viral Vectors
    13.3. Market Value Forecast, by Product Type, 2017-2031
        13.3.1. Consumables
        13.3.2. Equipment
            13.3.2.1. Cell Processing Equipment
            13.3.2.2. Single-use Equipment
            13.3.2.3. Other Equipment
        13.3.3. Software & Systems
    13.4. Market Value Forecast, by Technology, 2017-2031
        13.4.1. Cell Culture & Expansion
        13.4.2. Viral Vector Production
        13.4.3. Cell Sorting & Purification
        13.4.4. Gene Editing
        13.4.5. Others
    13.5. Market Value Forecast, by Indication, 2017-2031
        13.5.1. Oncology Disease
        13.5.2. Cardiovascular Disease
        13.5.3. Orthopedic Disease
        13.5.4. Infectious Disease
        13.5.5. Others
    13.6. Market Value Forecast, by End-user, 2017-2031
        13.6.1. Pharmaceutical & Biotechnology Companies
        13.6.2. Contract Manufacturing Organizations (CMOs)
    13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.7.1. Germany
        13.7.2. U.K.
        13.7.3. France
        13.7.4. Italy
        13.7.5. Spain
        13.7.6. Rest of Europe
    13.8. Market Attractiveness Analysis
        13.8.1. By Therapy Type
        13.8.2. By Product Type
        13.8.3. By Technology
        13.8.4. By Indication
        13.8.5. By End-user
        13.8.6. By Country/Sub-region
14. Asia Pacific Cell and Gene Therapy Manufacturing Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Therapy Type, 2017-2031
        14.2.1. Cell Therapy
            14.2.1.1. Allogeneic
                14.2.1.1.1. Mesenchymal Stem Cells
                14.2.1.1.2. T-cells
                14.2.1.1.3. Induced Pluripotent Stem Cells
                14.2.1.1.4. Natural Killer Cells
                14.2.1.1.5. Hematopoietic Stem Cells
                14.2.1.1.6. Others
            14.2.1.2. Autologous
                14.2.1.2.1. T-cells
                14.2.1.2.2. Hematopoietic Stem Cells
                14.2.1.2.3. Mesenchymal Stem Cells
                14.2.1.2.4. Natural Killer Cells
                14.2.1.2.5. Others
        14.2.2. Gene Therapy
            14.2.2.1. Viral Vector
                14.2.2.1.1. Lentiviral Vector
                14.2.2.1.2. Adeno-associated Virus Vectors
                14.2.2.1.3. Other Viral Vectors
            14.2.2.2. Non-viral Vector
                14.2.2.2.1. Electroporation
                14.2.2.2.2. Other Non-viral Vectors
    14.3. Market Value Forecast, by Product Type, 2017-2031
        14.3.1. Consumables
        14.3.2. Equipment
            14.3.2.1. Cell Processing Equipment
            14.3.2.2. Single-use Equipment
            14.3.2.3. Other Equipment
        14.3.3. Software & Systems
    14.4. Market Value Forecast, by Technology, 2017-2031
        14.4.1. Cell Culture & Expansion
        14.4.2. Viral Vector Production
        14.4.3. Cell Sorting & Purification
        14.4.4. Gene Editing
        14.4.5. Others
    14.5. Market Value Forecast, by Indication, 2017-2031
        14.5.1. Oncology Disease
        14.5.2. Cardiovascular Disease
        14.5.3. Orthopedic Disease
        14.5.4. Infectious Disease
        14.5.5. Others
    14.6. Market Value Forecast, by End-user, 2017-2031
        14.6.1. Pharmaceutical & Biotechnology Companies
        14.6.2. Contract Manufacturing Organizations (CMOs)
    14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.7.1. China
        14.7.2. Japan
        14.7.3. India
        14.7.4. Australia & New Zealand
        14.7.5. Rest of Asia Pacific
    14.8. Market Attractiveness Analysis
        14.8.1. By Therapy Type
        14.8.2. By Product Type
        14.8.3. By Technology
        14.8.4. By Indication
        14.8.5. By End-user
        14.8.6. By Country/Sub-region
15. Latin America Cell and Gene Therapy Manufacturing Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Therapy Type, 2017-2031
        15.2.1. Cell Therapy
            15.2.1.1. Allogeneic
                15.2.1.1.1. Mesenchymal Stem Cells
                15.2.1.1.2. T-cells
                15.2.1.1.3. Induced Pluripotent Stem Cells
                15.2.1.1.4. Natural Killer Cells
                15.2.1.1.5. Hematopoietic Stem Cells
                15.2.1.1.6. Others
            15.2.1.2. Autologous
                15.2.1.2.1. T-cells
                15.2.1.2.2. Hematopoietic Stem Cells
                15.2.1.2.3. Mesenchymal Stem Cells
                15.2.1.2.4. Natural Killer Cells
                15.2.1.2.5. Others
        15.2.2. Gene Therapy
            15.2.2.1. Viral Vector
                15.2.2.1.1. Lentiviral Vector
                15.2.2.1.2. Adeno-associated Virus Vectors
                15.2.2.1.3. Other Viral Vectors
            15.2.2.2. Non-viral Vector
                15.2.2.2.1. Electroporation
                15.2.2.2.2. Other Non-viral Vectors
    15.3. Market Value Forecast, by Product Type, 2017-2031
        15.3.1. Consumables
        15.3.2. Equipment
            15.3.2.1. Cell Processing Equipment
            15.3.2.2. Single-use Equipment
            15.3.2.3. Other Equipment
        15.3.3. Software & Systems
    15.4. Market Value Forecast, by Technology, 2017-2031
        15.4.1. Cell Culture & Expansion
        15.4.2. Viral Vector Production
        15.4.3. Cell Sorting & Purification
        15.4.4. Gene Editing
        15.4.5. Others
    15.5. Market Value Forecast, by Indication, 2017-2031
        15.5.1. Oncology Disease
        15.5.2. Cardiovascular Disease
        15.5.3. Orthopedic Disease
        15.5.4. Infectious Disease
        15.5.5. Others
    15.6. Market Value Forecast, by End-user, 2017-2031
        15.6.1. Pharmaceutical & Biotechnology Companies
        15.6.2. Contract Manufacturing Organizations (CMOs)
    15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.7.1. Brazil
        15.7.2. Mexico
        15.7.3. Rest of Latin America
    15.8. Market Attractiveness Analysis
        15.8.1. By Therapy Type
        15.8.2. By Product Type
        15.8.3. By Technology
        15.8.4. By Indication
        15.8.5. By End-user
        15.8.6. By Country/Sub-region
16. Middle East & Africa Cell and Gene Therapy Manufacturing Market Analysis and Forecast
    16.1. Introduction
        16.1.1. Key Findings
    16.2. Market Value Forecast, by Therapy Type, 2017-2031
        16.2.1. Cell Therapy
            16.2.1.1. Allogeneic
                16.2.1.1.1. Mesenchymal Stem Cells
                16.2.1.1.2. T-cells
                16.2.1.1.3. Induced Pluripotent Stem Cells
                16.2.1.1.4. Natural Killer Cells
                16.2.1.1.5. Hematopoietic Stem Cells
                16.2.1.1.6. Others
            16.2.1.2. Autologous
                16.2.1.2.1. T-cells
                16.2.1.2.2. Hematopoietic Stem Cells
                16.2.1.2.3. Mesenchymal Stem Cells
                16.2.1.2.4. Natural Killer Cells
                16.2.1.2.5. Others
        16.2.2. Gene Therapy
            16.2.2.1. Viral Vector
                16.2.2.1.1. Lentiviral Vector
                16.2.2.1.2. Adeno-associated Virus Vectors
                16.2.2.1.3. Other Viral Vectors
            16.2.2.2. Non-viral Vector
                16.2.2.2.1. Electroporation
                16.2.2.2.2. Other Non-viral Vectors
    16.3. Market Value Forecast, by Product Type, 2017-2031
        16.3.1. Consumables
        16.3.2. Equipment
            16.3.2.1. Cell Processing Equipment
            16.3.2.2. Single-use Equipment
            16.3.2.3. Other Equipment
        16.3.3. Software & Systems
    16.4. Market Value Forecast, by Technology, 2017-2031
        16.4.1. Cell Culture & Expansion
        16.4.2. Viral Vector Production
        16.4.3. Cell Sorting & Purification
        16.4.4. Gene Editing
        16.4.5. Others
    16.5. Market Value Forecast, by Indication, 2017-2031
        16.5.1. Oncology Disease
        16.5.2. Cardiovascular Disease
        16.5.3. Orthopedic Disease
        16.5.4. Infectious Disease
        16.5.5. Others
    16.6. Market Value Forecast, by End-user, 2017-2031
        16.6.1. Pharmaceutical & Biotechnology Companies
        16.6.2. Contract Manufacturing Organizations (CMOs)
    16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        16.7.1. GCC Countries
        16.7.2. South Africa
        16.7.3. Rest of Middle East & Africa
    16.8. Market Attractiveness Analysis
        16.8.1. By Therapy Type
        16.8.2. By Product Type
        16.8.3. By Technology
        16.8.4. By Indication
        16.8.5. By End-user
        16.8.6. By Country/Sub-region
17. Competition Landscape
    17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
    17.2. Market Share Analysis, by Company (2022)
    17.3. Company Profiles
        17.3.1. Becton, Dickinson and Company
            17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.1.2. Product Portfolio
            17.3.1.3. Financial Overview
            17.3.1.4. SWOT Analysis
            17.3.1.5. Strategic Overview
        17.3.2. Bio-Rad Laboratories, Inc.
            17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.2.2. Product Portfolio
            17.3.2.3. Financial Overview
            17.3.2.4. SWOT Analysis
            17.3.2.5. Strategic Overview
        17.3.3. Bio-Techne Corporation
            17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.3.2. Product Portfolio
            17.3.3.3. Financial Overview
            17.3.3.4. SWOT Analysis
            17.3.3.5. Strategic Overview
        17.3.4. Danaher Corporation
            17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.4.2. Product Portfolio
            17.3.4.3. Financial Overview
            17.3.4.4. SWOT Analysis
            17.3.4.5. Strategic Overview
        17.3.5. General Electric Company (GE Healthcare)
            17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.5.2. Product Portfolio
            17.3.5.3. Financial Overview
            17.3.5.4. SWOT Analysis
            17.3.5.5. Strategic Overview
        17.3.6. Getinge AB
            17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.6.2. Product Portfolio
            17.3.6.3. Financial Overview
            17.3.6.4. SWOT Analysis
            17.3.6.5. Strategic Overview
        17.3.7. Lonza Group Ltd.
            17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.7.2. Product Portfolio
            17.3.7.3. Financial Overview
            17.3.7.4. SWOT Analysis
            17.3.7.5. Strategic Overview
        17.3.8. Merck KGaA
            17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.8.2. Product Portfolio
            17.3.8.3. Financial Overview
            17.3.8.4. SWOT Analysis
            17.3.8.5. Strategic Overview
        17.3.9. Sartorius AG (Sartorius Stedim Biotech S.A.)
            17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.9.2. Product Portfolio
            17.3.9.3. Financial Overview
            17.3.9.4. SWOT Analysis
            17.3.9.5. Strategic Overview
        17.3.10. Thermo Fisher Scientific Inc.
            17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.10.2. Product Portfolio
            17.3.10.3. Financial Overview
            17.3.10.4. SWOT Analysis
            17.3.10.5. Strategic Overview
        17.3.11. MaxCyte
            17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.11.2. Product Portfolio
            17.3.11.3. Financial Overview
            17.3.11.4. SWOT Analysis
            17.3.11.5. Strategic Overview
        17.3.12. Fresenius Medical Care AG & Co. KGaA
            17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.12.2. Product Portfolio
            17.3.12.3. Financial Overview
            17.3.12.4. SWOT Analysis
            17.3.12.5. Strategic Overview